1 July 2007 in European Journal of Vascular and Endovascular Surgery
1 November 2008 in Journal of Vascular Surgery
1 December 2008 in Journal of Vascular Surgery
30 November 2006 in Journal of Vascular Surgery
BABeatrice R. Amann-Vesti
1 July 2006 in Journal of Vascular Research
BABeatrice R. Amann-Vesti
Background: Direct assessment of the effect of postural changes on interstitial fluid pressure (IFP) in the human skin under physiological conditions is important for the understanding of mechanisms involved in diseases resulting in lower limb edema. Previous techniques to measure IFP had limitations of being invasive, and acute measurements were not possible. Here we describe the effect of postural changes on IFP in the skin of the foot using the minimally invasive servonulling technique. Results: Measurements were performed in 12 healthy subjects. IFP (means ± SD) was significantly higher in the sitting (5.1 ± 2.9 mm Hg) than in the supine position (–0.3 ± 3.6 mm Hg, p = 0.04) when measured in the sitting position first. The difference between the sitting and the supine position was not significant when measurements were taken in the supine position first [from 1.0 ± 4.3 (supine) to 3.6 ± 6.7 mm Hg (sitting), p = 0.46]. Spontaneous low-frequency pressure fluctuations occurred in 58% of the recordings during sitting, which was almost twice as frequent as in the supine position (33%; p = 0.001), while no effects on lymphatic capillary network extension were observed (p = 0.12). Conclusion: Using the servonulling micropressure system, postural effects on IFP can be directly assessed. IFP is higher in the sitting position, but differences are influenced by the time in the upright position.
26 April 2007 in Expert Opinion on Investigational Drugs
Adverse cardiovascular events are the consequence of a molecular chain reaction at the site of vulnerable plaques. Key players are platelets and coagulation factors that are activated following plaque rupture and often cause arterial obstruction. Thrombin, a plasma serine protease, plays a role in hemostasis of coagulation as well as in thrombosis and cell growth, leading to restenosis and atherosclerosis. Interesting and promising new molecules, the direct thrombin inhibitors, have been shown to be as effective as the combination of glycoprotein IIb–IIIa inhibitors and heparin for the prevention of arterial thrombosis. Until recently, direct thrombin inhibitiors could be applied only parenterally; therefore, therapy was limited to hospitalized patients. As a result of recent drug development, orally active direct thrombin inhibitors are now available and have been evaluated for the long-term treatment of venous thrombosis and arterial fibrillation. Due to their specific pharmocodynamic characteristics by binding directly to thrombin – and thus inhibiting platelet aggregation and fibrin generation – these novel drugs may also have therapeutic potential for the treatment of atherothrombotic disease and its complications such as myocardial infarction, stroke or limb ischemia.